Clark Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12K Buy
23
+19
+475% +$9.7K 0.01% 237
2026
Q2
$1.99K Sell
4
-9
-69% -$3.99K ﹤0.01% 418
2026
Q1
$5.81K Hold
13
– – ﹤0.01% 315
2025
Q4
$5.89K Hold
13
– – ﹤0.01% 312
2025
Q3
$5.89K Buy
+13
New +$5.43K ﹤0.01% 312
2025
Q2
– Sell
-13
Closed -$6.3K – 632
2025
Q1
$6.3K Hold
13
– – ﹤0.01% 251
2024
Q4
$5.24K Buy
+13
New +$6.03K ﹤0.01% 232

Other funds holding VRTX

Clark Wealth Partners's VRTX Position: Q3 2026 in Review

Clark Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 475% in Q3 2026, buying an estimated $9.7K and bringing the position to 23 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #237.

Clark Wealth Partners first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Clark Wealth Partners held 23 shares of Vertex Pharmaceuticals worth $12K as of Q3 2026.
  • Clark Wealth Partners bought 19 Vertex Pharmaceuticals shares in Q3 2026, an estimated $9.7K.
  • Vertex Pharmaceuticals made up 0.01% of Clark Wealth Partners's portfolio in Q3 2026, its #237 holding.
  • Clark Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Clark Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.